{"id":"W2209368665","doi":"10.1016/s0140-6736(15)00817-x","title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1264,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Placebo; Medicine; Gastrointestinal tract; Internal medicine; Lung; Neuroendocrine tumors; Oncology; Gastroenterology; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05816962875443518,"score_gpt":0.3631413652564144,"score_spread":0.3049717365019792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}